

AJJ MEDTECH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 198403368H)

PROPOSED PLACEMENT OF AN AGGREGATE OF 127,499,998 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY

- RECEIPT OF LISTING AND QUOTATION NOTICE

1. INTRODUCTION

The Board of Directors (the “**Board**” or “**Directors**”) of AJJ Medtech Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the Company’s announcement dated 3 November 2025 (the “**Previous Announcement**”) in relation to the proposed placement (the “**Placement**”) of an aggregate of 127,499,998 new ordinary shares (the “**Placement Shares**”) at an issue price of S\$0.0072 (the “**Placement Price**”) to several investors (the “**Placees**”).

Unless otherwise defined herein, all capitalised terms used herein shall have the meanings ascribed to them in the Previous Announcement.

2. RECEIPT OF LISTING AND QUOTATION NOTICE

The Board wishes to announce that the Company has on 19 November 2025 received the listing and quotation notice (the “**LQN**”) from the SGX-ST for the listing and quotation of an aggregate of 127,499,998 Placement Shares on the Catalist board of the SGX-ST, subject to the Company’s compliance with the SGX-ST’s listing requirements.

Pursuant to the LQN, the Placement Shares have to be placed out within 7 market days from the date of the LQN.

The LQN is not to be taken as an indication of the merits of the Placement, the Placement Shares, the Company, its subsidiaries and their securities.

The Company will make the necessary announcement(s) upon the completion of the Placement.

3. TRADING CAUTION

Shareholders are advised to exercise caution in trading their Shares. The Placement is subject to certain conditions. There is no certainty or assurance as at the date of this announcement that the Placement will be completed or that no changes will be made to the terms thereof. The Company will make the necessary announcements when there are further developments. Shareholders and potential investors are advised to read this announcement and any further announcements by the Company carefully. Shareholders and potential investors should consult their stock brokers, bank managers, solicitors or other professional advisors if they have any doubt about the actions they should take.

By Order of the Board

Zhao Xin
Chief Executive Officer and Executive Director

19 November 2025

This document has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.